MD Anderson Cancer Center

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
	Symptom Inventory for Gastrointestinal Stromal Tumors	Ongoing, but not recruiting	Closed		NCT01178307